Alkermes (ALKS) Stock Price, News & Analysis

Company Overview

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: $26.67 to $27.59
• 50-Day Range: $26.13 to $31.71
• 52-Week Range: $25.56 to $36.45
• Volume: 306,132 shs
• Average Volume: 1.77 million shs
• Market Capitalization: $4.47 billion
• P/E Ratio: 12.98
• Dividend Yield: N/A
• Price Target: $40.92
• Consensus Rating: Moderate Buy

Alkermes Stock Analysis - MarketRank™

Alkermes scored higher than 96% of companies evaluated by MarketBeat, and ranked 50th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Alkermes has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.58%

Earnings Growth

Earnings for Alkermes are expected to grow by 4.58% in the coming year, from $1.31 to $1.37 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alkermes is 12.92, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.89.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alkermes is 12.92, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.19.

Price to Earnings Growth Ratio

Alkermes has a PEG Ratio of 1.60. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Alkermes has a P/B Ratio of 2.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.52% of the float of Alkermes has been sold short.

Short Interest Ratio / Days to Cover

Alkermes has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Alkermes has recently increased by 12.31%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alkermes does not currently pay a dividend.

Dividend Growth

Alkermes does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.17

Percentage of Shares Shorted

7.52% of the float of Alkermes has been sold short.

Short Interest Ratio / Days to Cover

Alkermes has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Alkermes has recently increased by 12.31%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.81

News Sentiment

Alkermes has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Alkermes this week, compared to 8 articles on an average week.

Search Interest

11 people have searched for ALKS on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.

MarketBeat Follows

2 people have added Alkermes to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $210,143.00 in company stock.

Percentage Held by Insiders

Only 4.40% of the stock of Alkermes is held by insiders.

Percentage Held by Institutions

95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALKS Stock Analysis - Frequently Asked Questions

How have ALKS shares performed this year?

Alkermes' stock was trading at $28.76 at the beginning of 2025. Since then, ALKS stock has decreased by 6.1% and is now trading at $27.00.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) issued its earnings results on Tuesday, July, 29th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.10. The company's revenue was down 2.1% on a year-over-year basis.
Read the conference call transcript.

Is Alkermes doing a stock buyback?

Alkermes' Board of Directors approved a stock buyback program on Thursday, February 15th 2024, which allows the company to buy back $400,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 8.2% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's management believes its shares are undervalued.

Does Alkermes have any subsidiaries?

Alkermes subsidiaries include Rodin Therapeutics.

Who are Alkermes' major shareholders?

Top institutional investors of Alkermes include Atle Fund Management AB (0.14%), TD Asset Management Inc (0.13%), Aberdeen Group plc (0.11%) and Wedge Capital Management L L P NC (0.08%). Insiders that own company stock include Christian Todd Nichols, Craig C Hopkinson, Cato T Laurencin and Nancy Wysenski.
View institutional ownership trends.

How do I buy shares of Alkermes?

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALKS
• CIK: 1520262
• Web: www.alkermes.com
• Phone: (531) 772-8000
• Fax: 781-890-0524
• Employees: 1,800
• Year Founded: 1987

Price Target and Rating

• Average Price Target for Alkermes: $40.92
• High Price Target: $52.00
• Low Price Target: $26.00
• Potential Upside/Downside: +51.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.09
• Trailing P/E Ratio: 12.92
• Forward P/E Ratio: 20.61
• P/E Growth: 1.6
• Net Income: $367.07 million
• Net Margins: 23.30%
• Pretax Margin: 27.90%
• Return on Equity: 27.52%
• Return on Assets: 17.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.33
• Quick Ratio: 2.92

Sales & Book Value

• Annual Sales: $1.51 billion
• Price / Sales: 2.94
• Cash Flow: $2.74 per share
• Price / Cash Flow: 9.86
• Book Value: $9.05 per share
• Price / Book: 2.98

Miscellaneous

• Outstanding Shares: 164,901,000
• Free Float: 157,645,000
• Market Cap: $4.45 billion
• Optionable: Optionable
• Beta: 0.44